Menu Search
Equities

Medlab Clinical Ltd

MDBBF:PKC

Medlab Clinical Ltd

Actions
  • Price (USD)0.105
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Feb 17 2022.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Medlab Clinical Limited (Medlab) is an Australia-based biotechnology company focused on the development and commercialization of a pharmaceutical delivery platform. The Company is investigating a range of prescription and non-prescription solutions for unmet patient needs across a variety of therapeutic areas, including pain management, mental health, gut health, diabetes, and allergies. The Company’s drug candidates include NanaBis, NanoCBD and NanoCelle. Medlab’s pipeline comprises a range of small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies. The Company's lead drug candidate, NanaBis, is under development for cancer bone pain as an alternative to opioid use and NanoCBD for mental stress . The Company also has a drug delivery platform called NanoCelle, which is wholly owned by Medlab and developed in Medlab’s owned Office of the Gene Technology Regulator (OGTR) registered laboratory.

  • Revenue in AUD (TTM)366.64k
  • Net income in AUD-3.94m
  • Incorporated2014
  • Employees14.00
  • Location
    Medlab Clinical LtdUnits 5 And 6 11 Lord Street BotanyALEXANDRIA 2019AustraliaAUS
  • Phone+61 28188-0311
  • Fax+61 29699-3347
  • Websitehttps://www.medlab.co/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.